Türkiye's latest Sterile Inhalation Facility that went into operation in collaboration with GSK Türkiye and Abdi İbrahim and with the support of the Investment Office was officially inaugurated at the Abdi İbrahim Esenyurt Production Complex. The facility leverages the two companies' cutting-edge technology, know-how, and experience, with the goal of contributing to the localization of pharmaceutical production in Türkiye and producing 600 million nebules worth TRY 2 billion over the next five years.
The GSK-developed nebule technology is used as a medicine to treat respiratory diseases and will be produced in the Sterile Inhalation Facility located at Turkish pharmaceutical pioneer Abdi İbrahim's Esenyurt Production Complex, benefiting substantially both to public health and the Turkish economy. The facility, established with a TRY 340 million investment, meets international standards and is GSK Türkiye's largest investment in the past decade. It also stands out as the only production center in the world where the company's entire nebule portfolio is produced.
In his remarks at the opening, Investment Office President A. Burak Dağlıoğlu said, “Since 2003, under the leadership of President Recep Tayyip Erdoğan, many reforms have been carried out for the development of our country, encouraging investments, and driving exports by supporting R&D and innovation in life sciences as well as in other sectors. Ranking in the list of top 20 global pharmaceutical markets with a size of USD 7 billion, Türkiye is on the radar of the global health ecosystem. Investment Office pursues qualified investments that will cement collaboration between Turkish and international businesses."
GSK Türkiye General Manager Selim Giray stated that the respiratory diseases such as asthma and COPD are among the most important social health issues across the globe and in Türkiye. He added, “We know that these diseases affect around 8 million people in our country. With this state-of-the-art know-how transfer from the GSK production facility in Australia to our country under the leadership of a huge team, we are happy to deliver a facility of global standards to Türkiye and contribute to the localization of pharmaceutical production."
Abdi İbrahim General Manager Dr. Süha Taşpolatoğlu commented on the new investment, saying, “This project has crowned our over 30-year valuable business partnership with GSK and is the sole production center in the world where GSK's entire nebule portfolio is produced. Breathing is a strategic area for Abdi İbrahim, and we are honored that GSK chose us to invest in this field."